First filed August, 2019, updated January, 2021
CATEGORIES: General SLE
This phase 2b, multi-center, double-blind, randomized, placebo-controlled, 52-week, dose-ranging study is investigating AMG 570 in subjects with active SLE who have had inadequate response to SOC therapies including oral corticosteroids (OCS), immunosuppressants and immunomodulators.
This study is being offered at 24 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.
24 LuCIN sites (U.S. and Canada)